[1]梁雁雁,樊芳,贾志旸.玻璃体内注射雷珠单抗后视网膜静脉阻塞性黄斑水肿复发的预测因素分析[J].眼科新进展,2022,42(10):802-805.[doi:10.13389/j.cnki.rao.2022.0165]
　LIANG Yanyan,FAN Fang,JIA Zhiyang.Predictors of recurrence of retinal vein occlusion-related macular edema after intravitreal injection of ranibizumab[J].Recent Advances in Ophthalmology,2022,42(10):802-805.[doi:10.13389/j.cnki.rao.2022.0165]
点击复制

玻璃体内注射雷珠单抗后视网膜静脉阻塞性黄斑水肿复发的预测因素分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年10期
页码:
802-805
栏目:
应用研究
出版日期:
2022-10-05

文章信息/Info

Title:
Predictors of recurrence of retinal vein occlusion-related macular edema after intravitreal injection of ranibizumab
作者:
梁雁雁; 樊芳; 贾志旸
063210　河北省唐山市，华北理工大学（梁雁雁）；050051　河北省石家庄市，河北省人民医院（梁雁雁， 樊芳，贾志旸）
Author(s):
LIANG Yanyan1; 2; FAN Fang2; JIA Zhiyang2
1.North China University of Science and Technology,Tangshan 063210，Hebei Province，China
2.Hebei General Hospital,Shijiazhuang 050051,Hebei Province，China
关键词:
视网膜静脉阻塞; 黄斑水肿; 视网膜厚度; 雷珠单抗
Keywords:
retinal vein occlusion;  macular edema;  retinal thickness;  ranibizumab
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2022.0165
文献标志码:
A
摘要:
目的　探索玻璃体内注射雷珠单抗治疗视网膜静脉阻塞(RVO)性黄斑水肿（ME）的复发因素。方法　纳入2020年1月至2021年4月河北省人民医院眼科收治的未经治疗的RVO性ME患者，所有患者均接受玻璃体内注射雷珠单抗治疗（1+PRN方案）。记录患者接受治疗前的性别、年龄、眼别、病程、RVO类型、最佳矫正视力（BCVA）、黄斑区结构改变、视网膜激光治疗史以及高血压病史、总胆固醇、甘油三酯等情况。根据注射雷珠单抗的次数将患者分为未复发组和复发组，比较两组患者在接受玻璃体内注射雷珠单抗治疗前基线资料的差异，利用Logistic回归分析探索影响RVO性ME复发的危险因素。结果　62例（62眼）纳入研究，其中未复发组27例，复发组35例，比较两组患者间的基线资料，复发组患者的基线黄斑中央凹视网膜厚度（CRT）、伴有视网膜高反射病灶（HRF）以及高血压的概率均高于未复发组（均为P<0.05）。二元Logistic回归分析结果显示，基线CRT厚和伴有HRF是RVO性ME复发的高危因素（CRT:OR=1.003,P=0.041;HRF：OR=0.293,P=0.040）。Logistic回归模型分析结果显示，基线CRT与玻璃体内注射次数密切相关，基线CRT越厚，后续治疗中需要玻璃体内注射的次数越多（OR=1.003,P=0.018）。结论　基线CRT厚和伴有HRF是RVO性ME复发的主要危险因素，可用于临床早期预测RVO性ME的复发。
Abstract:
Objective　To explore the risk factors for recurrence of retinal vein occlusion-related macular edema (RVO-ME) after intravitreal injection of ranibizumab. Methods　Patients with untreated RVO-ME admitted to the Ophthalmology Department of Hebei General Hospital from January 2020 to April 2021 were included, and all of them received intravitreal injection of ranibizumab (1+PRN). Patients’ gender, age, eyes, disease duration, RVO type, best corrected visual acuity, macular structural changes, history of retinal laser therapy, history of hypertension, total cholesterol, and triglycerides before treatment were recorded. Patients were divided into the non-recurrence and recurrence groups according to the number of injections of ranibizumab, and the differences in baseline data between the two groups before intravitreal injection of ranibizumab were compared to explore the risk factors for recurrence of RVO-ME using Logistic regression analysis. Results　Sixty-two patients (62 eyes) were included in the study, including 27 in the non-recurrence group and 35 in the recurrence group. Before treatment, the central retinal thickness (CRT), hyperreflective foci (HRF), and prevalence of hypertension in the recurrence group were higher than those in the non-recurrence group (all P<0.05). The bivariate Logistic regression analysis results showed that baseline CRT and HRF were high-risk factors for recurrence of RVO-ME (CRT: OR=1.003, P=0.041; HRF: OR=0.293, P=0.040), in which baseline CRT was more closely related to the number of intravitreal injections. The higher the baseline CRT was, the more the subsequent intravitreal injections were needed (OR=1.003, P=0.018). Conclusion　Baseline CRT and HRF are the main risk factors for recurrence of RVO-ME and can be used for early prediction of recurrence of RVO-ME.

参考文献/References:

［1］　RAHIMY E,RAYESS N,BRADY C J,REGILLO C D.Treat-and-extend regimen for macular edema secondary to central retinal vein occlusion:12-month results［J］．Ophthalmol Retina,2017,1(2):118-123.
［2］　邓雪晴,王峰,李宇博,唐子雁,苏颖.视网膜静脉阻塞相关血液学研究新进展［J］．中国实用眼科杂志,2017,35(4):358-362.
DENG X Q,WANG F,LI Y B,TANG Z Y,SU Y.New advances in hematological studies related to retinal vein occlusion［J］．Chin J Pract Ophthalmol,2017,35(4):358-362.
［3］　YILMAZ T B,KARABAS L,OZKAN B.Impact of intravitreal dexamethasone implant on vessel diameters in patients with retinal vein occlusion［J］．J Ophthalmol,2019,2019:3982428.
［4］　NOMA H,MIMURA T,YASUDA K,SHIMURA M.Cytokine kinetics after monthly intravitreal bevacizumab for retinal vein occlusion associated with macular oedema［J］．Ophthalmic Res,2016,56(4):207-214.
［5］　NOMA H,FUNATSU H,MIMURA T.Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion［J］．Curr Eye Res,2012,37(1):62-67.
［6］　GONZALEZ-GARCIA A,MENDOZA-SANTIESTEBAN C E,MENDOZA-SANTIESTEBAN E A,FELIPE D L,ECHAVARRIA O H,SANTIESTEBAN-FREIXAS R,et al.Ischemic optic neuropathy［J］．Semin Ophthalmol,2010,25(4):130-135.
［7］　YOO J H,AHN J,OH J,CHA J,KIM S W.Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection［J］．Br J Ophthalmol,2017,101(10):1334-1339.
［8］　JUMPER J M,DUGEL P,CHEN S,BLINDER K J,WALT J G.Anti-VEGF treatment of macular edema associated with retinal vein occlusion:patterns of use and effectiveness in clinical practice (ECHO study report 2)［J］．Clin Ophthalmol,2018,12:621-629.
［9］　HASEGAWA T,TAKAHASHI Y,MARUKO I,KOGURE A,IIDA T.Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion［J］．Br J Ophthalmol,2019,103(10):1367-1372.
［10］　KUMAGAI K,TSUJIKAWA A,MURAOKA Y,AKAGI-KURASHIGE Y,MURAKAMI T,MIYAMOTO K,et al.Three-dimensional optical coherence tomography evaluation of vascular changes at arteriovenous crossings［J］．Invest Ophthalmol Vis Sci,2014,55(3):1867-1875.
［11］　尹小芳,叶祖科,汤秀容,梁影影,黎彦豪,罗书科,等.玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析［J］．眼科新进展,2020,40(1):46-49.
YIN X F,YE Z K,TANG X R,LIANG Y Y,LI Y H,LUO S K,et al.Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of ranibizumab treatment［J］．Rec Adv Ophthalmol,2020,40(1):46-49.
［12］　NOMA H,MIMURA T,YASUDA K,NAKAGAWA H,MOTOHASHI R,KOTAKE O,et al.Cytokines and recurrence of macular edema after intravitreal ranibizumab in patients with branch retinal vein occlusion［J］．Ophthalmologica,2016,236(4):228-234.
［13］　TILGNER E,DALCEGIO F M,TUISL M,WIEDEMANN P,REHAK M.Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion［J］．Acta Ophthalmol,2017,95(7):e592-e596.
［14］　COSTA J V,MOURA-COELHO N,ABREU A C,NEVES P,ORNELAS M,FURTADO M J.Macular edema secondary to retinal vein occlusion in a real-life setting:a multicenter,nationwide,3-year follow-up study［J］．Graefes Arch Clin Exp Ophthalmol,2021,259(2):343-350.
［15］　SUZUKI M,NAGAI N,MINAMI S,KURIHARA T,KAMOSHITA M,SONOBE H,et al.Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy［J］．Graefes Arch Clin Exp Ophthalmol,2020,258(1):49-56.
［16］　MOEIN H R,NOVAIS E A,REBHUN C B,COLE E D,LOUZADA R N,WITKIN A J,et al.Optical coherence tomography angiography to detect macular capillary ischemia in patients with inner retinal changes after resolved diabetic macular edema［J］．Retina,2018,38(12):2277-2284.
［17］　GRIGSBY J G,CARDONA S M,POUW C E,MUNIZ A,MENDIOLA A S,TSIN A T,et al.The role of microglia in diabetic retinopathy［J］．J Ophthalmol,2014,2014 :705783.
［18］　THAPA R,BAJIMAYA S,PAUDYAL G,KHANAL S,TAN S,THAPA S S,et al.Prevalence,pattern and risk factors of retinal vein occlusion in an elderly population in Nepal:the Bhaktapur retina study［J］．BMC Ophthalmol,2017,17(1):162.
［19］　TOMITA R,IWASE T,GOTO K,YAMAMOTO K,RA E,TERASAKI H.Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion［J］．Sci Rep,2019,9(1):16388.
［20］　KIDA T,MORISHITA S,KAKURAI K,SUZUKI H,OKU H,IKEDA T.Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion［J］．Clin Ophthalmol,2014,8:955-958.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[4]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[5]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[6]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[7]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[8]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[9]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[12]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[13]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(10):070.[doi:10.13389/j.cnki.rao.2016.0020]
[14]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(10):471.[doi:10.13389/j.cnki.rao.2016.0126]
[15]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061.[doi:10.13389/j.cnki.rao.2016.0283]
　ZHANG Min,ZHU Jian-Hua,FENG Hao,et al.Macular microstructure changes in retinal vein occlusion and its correlation with visual acuity[J].Recent Advances in Ophthalmology,2016,36(10):1061.[doi:10.13389/j.cnki.rao.2016.0283]
[16]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(10):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[17]马为梅,雷晓琴,田芳,等.视网膜静脉阻塞黄斑水肿的多焦视网膜电图与光学相干断层扫描分析[J].眼科新进展,2017,37(7):651.[doi:10.13389/j.cnki.rao.2017.0165]
　MA Wei-Mei,LEI Xiao-Qin,TIAN Fang,et al.Multifocal electroretinogram and optical coherence tomography characteristics of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(10):651.[doi:10.13389/j.cnki.rao.2017.0165]
[18]李筱荣,周怀蔚.重视黄斑水肿的病因、治疗及预防[J].眼科新进展,2019,39(7):601.[doi:10.13389/j.cnki.rao.2019.0139]
　LI Xiao-Rong,ZHOU Huai-Yu.Special attention to the cause,treatment and prevention of macular edema[J].Recent Advances in Ophthalmology,2019,39(10):601.[doi:10.13389/j.cnki.rao.2019.0139]
[19]梁婉玲,周怀胜,马海智,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效[J].眼科新进展,2019,39(7):666.[doi:10.13389/j.cnki.rao.2019.0153]
　LIANG Wan-Ling,ZHOU Huai-Sheng,MA Hai-Zhi,et al.The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(10):666.[doi:10.13389/j.cnki.rao.2019.0153]
[20]栗怡然,朱瑞琳,杨柳.炎症在视网膜静脉阻塞性黄斑水肿中的作用[J].眼科新进展,2020,40(1):090.[doi:10.13389/j.cnki.rao.2020.0023]
　LI Yiran,ZHU Ruilin,YANG Liu.Role of inflammation in macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(10):090.[doi:10.13389/j.cnki.rao.2020.0023]

备注/Memo

备注/Memo:
河北省卫生与健康委员会重点科研研究计划 (编号：20180078)
更新日期/Last Update: 2022-10-05